Loading
NASDAQHealthcareMedical - Devices
Latest quote
$1.50
−$0.16 · -9.64%
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Latest quote
$1.50
−$0.16 · -9.64%
After-hours
$1.52
+$0.02 · +1.33%
Oct 7, 7:57 PM ET
Regular session · ET · Market data may be delayed.
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Day range
Current $1.50
52-week range
Current $1.50
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
50
Mixed
Risk
66
High Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Day range
Current $1.50
52-week range
Current $1.50
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 2.8M USD | 1.61M USD | 2.04M USD | 4.2M USD | 7.66M USD |
| Selling, general, and administrative | 24.9M USD | 2.99M USD | 4.08M USD | 5.24M USD | 4.77M USD |
| Operating expenses | 13.22M USD | 4.5M USD | 6.07M USD | 11.14M USD | 11.69M USD |
| Interest expense | 5.1M USD | 4.42M USD | 4.28M USD | 6.27M USD | 4.08M USD |
| Depreciation and amortization | — | — | — | 724K USD | 1.18M USD |
| Operating income | −13.22M USD | −4.5M USD | −6.07M USD | −11.14M USD | −11.69M USD |
| Net income | −35.82M USD | −9.23M USD | −10.28M USD | −20.22M USD | −10.31M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 17, 2026 | 1:4 | — | — |
Stock split | Jul 7, 2026 | 1:25 | — | — |
Stock split | Feb 9, 2026 | 1:75 | — | — |
Effective Aug 17, 2026
1:4
Effective Jul 7, 2026
1:25
Effective Feb 9, 2026
1:75
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
